Cargando…
Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension
Pulmonary arterial hypertension is a severe and progressive disease characterized by a pulmonary vascular remodeling process with expansion of collateral endothelial cells and total vessel occlusion. Endothelial cells are believed to be at the forefront of the disease process. Vascular endothelial g...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471204/ https://www.ncbi.nlm.nih.gov/pubmed/32880713 http://dx.doi.org/10.1007/s00395-020-0811-5 |
_version_ | 1783578735458385920 |
---|---|
author | Winter, Max-Paul Sharma, Smriti Altmann, Johanna Seidl, Veronika Panzenböck, Adelheid Alimohammadi, Arman Zelniker, Thomas Redwan, Bassam Nagel, Felix Santer, David Stieglbauer, Alexander Podesser, Bruno Sibilia, Maria Helbich, Thomas Prager, Gerald Ilhan-Mutlu, Aysegül Preusser, Matthias Lang, Irene M. |
author_facet | Winter, Max-Paul Sharma, Smriti Altmann, Johanna Seidl, Veronika Panzenböck, Adelheid Alimohammadi, Arman Zelniker, Thomas Redwan, Bassam Nagel, Felix Santer, David Stieglbauer, Alexander Podesser, Bruno Sibilia, Maria Helbich, Thomas Prager, Gerald Ilhan-Mutlu, Aysegül Preusser, Matthias Lang, Irene M. |
author_sort | Winter, Max-Paul |
collection | PubMed |
description | Pulmonary arterial hypertension is a severe and progressive disease characterized by a pulmonary vascular remodeling process with expansion of collateral endothelial cells and total vessel occlusion. Endothelial cells are believed to be at the forefront of the disease process. Vascular endothelial growth factor (VEGF) and its tyrosine kinase receptor, VEGF receptor-2 (VEGFR-2), play a central role in angiogenesis, endothelial cell protection, but also in the destabilization of endothelial barrier function. Therefore, we investigated the consequences of altered VEGF signaling in an experimental model, and looked for translational correlates of this observation in patients. We performed an endothelial cell-specific conditional deletion of the kinase insert domain protein receptor (kdr) gene, coding for VEGFR-2, in C57/BL6 mice (Kdr(∆end)) and held them in an environmental chamber with 10% FiO(2) or under normoxia for 6 weeks. Kdr knockout led to a mild PH phenotype under normoxia that worsened under hypoxia. Kdr(∆end) mice exhibited a significant increase in pulmonary arterial wall thickness, muscularization, and VEGFR-3(+) endothelial cells obliterating the pulmonary artery vessel lumen. We observed the same proliferative vasculopathy in our rodent model as seen in patients receiving anti-angiogenic therapy. Serum VEGF-a levels were elevated both in the experimental model and in humans receiving bevacizumab. Interrupted VEGF signaling leads to a pulmonary proliferative arteriopathy in rodents after direct ablative gene manipulation of Kdr. Histologically, similar vascular lesions can be observed in patients receiving anti-VEGF treatment. Our findings illustrate the importance of VEGF signaling for maintenance of pulmonary vascular patency. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00395-020-0811-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7471204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-74712042020-09-16 Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension Winter, Max-Paul Sharma, Smriti Altmann, Johanna Seidl, Veronika Panzenböck, Adelheid Alimohammadi, Arman Zelniker, Thomas Redwan, Bassam Nagel, Felix Santer, David Stieglbauer, Alexander Podesser, Bruno Sibilia, Maria Helbich, Thomas Prager, Gerald Ilhan-Mutlu, Aysegül Preusser, Matthias Lang, Irene M. Basic Res Cardiol Original Contribution Pulmonary arterial hypertension is a severe and progressive disease characterized by a pulmonary vascular remodeling process with expansion of collateral endothelial cells and total vessel occlusion. Endothelial cells are believed to be at the forefront of the disease process. Vascular endothelial growth factor (VEGF) and its tyrosine kinase receptor, VEGF receptor-2 (VEGFR-2), play a central role in angiogenesis, endothelial cell protection, but also in the destabilization of endothelial barrier function. Therefore, we investigated the consequences of altered VEGF signaling in an experimental model, and looked for translational correlates of this observation in patients. We performed an endothelial cell-specific conditional deletion of the kinase insert domain protein receptor (kdr) gene, coding for VEGFR-2, in C57/BL6 mice (Kdr(∆end)) and held them in an environmental chamber with 10% FiO(2) or under normoxia for 6 weeks. Kdr knockout led to a mild PH phenotype under normoxia that worsened under hypoxia. Kdr(∆end) mice exhibited a significant increase in pulmonary arterial wall thickness, muscularization, and VEGFR-3(+) endothelial cells obliterating the pulmonary artery vessel lumen. We observed the same proliferative vasculopathy in our rodent model as seen in patients receiving anti-angiogenic therapy. Serum VEGF-a levels were elevated both in the experimental model and in humans receiving bevacizumab. Interrupted VEGF signaling leads to a pulmonary proliferative arteriopathy in rodents after direct ablative gene manipulation of Kdr. Histologically, similar vascular lesions can be observed in patients receiving anti-VEGF treatment. Our findings illustrate the importance of VEGF signaling for maintenance of pulmonary vascular patency. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00395-020-0811-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-09-03 2020 /pmc/articles/PMC7471204/ /pubmed/32880713 http://dx.doi.org/10.1007/s00395-020-0811-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Contribution Winter, Max-Paul Sharma, Smriti Altmann, Johanna Seidl, Veronika Panzenböck, Adelheid Alimohammadi, Arman Zelniker, Thomas Redwan, Bassam Nagel, Felix Santer, David Stieglbauer, Alexander Podesser, Bruno Sibilia, Maria Helbich, Thomas Prager, Gerald Ilhan-Mutlu, Aysegül Preusser, Matthias Lang, Irene M. Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension |
title | Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension |
title_full | Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension |
title_fullStr | Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension |
title_full_unstemmed | Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension |
title_short | Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension |
title_sort | interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension |
topic | Original Contribution |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471204/ https://www.ncbi.nlm.nih.gov/pubmed/32880713 http://dx.doi.org/10.1007/s00395-020-0811-5 |
work_keys_str_mv | AT wintermaxpaul interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT sharmasmriti interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT altmannjohanna interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT seidlveronika interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT panzenbockadelheid interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT alimohammadiarman interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT zelnikerthomas interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT redwanbassam interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT nagelfelix interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT santerdavid interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT stieglbaueralexander interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT podesserbruno interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT sibiliamaria interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT helbichthomas interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT pragergerald interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT ilhanmutluaysegul interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT preussermatthias interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension AT langirenem interruptionofvascularendothelialgrowthfactorreceptor2signalinginducesaproliferativepulmonaryvasculopathyandpulmonaryhypertension |